<?xml version="1.0" encoding="UTF-8"?>
<wcm:root xmlns:wcm="http://www.stellent.com/wcm-data/ns/8.0.0">
  <wcm:element name="MainContent">&lt;table border="1" summary="Date and time information for the Meeting of the Blood Products Advisory Committee" cellpadding="3" width="98%"&gt;&lt;tbody&gt;&lt;tr align="left" bgcolor="#cccccc"&gt;&lt;th valign="top" scope="col"&gt;&lt;p&gt;&lt;strong&gt;Center &lt;/strong&gt;&lt;/p&gt;&lt;/th&gt;&lt;th valign="top" scope="col"&gt;&lt;p&gt;&lt;strong&gt;Date &lt;/strong&gt;&lt;/p&gt;&lt;/th&gt;&lt;th valign="top" scope="col"&gt;&lt;p&gt;&lt;strong&gt;Time &lt;/strong&gt;&lt;/p&gt;&lt;/th&gt;&lt;th valign="top" scope="col"&gt;&lt;p&gt;&lt;strong&gt;Location &lt;/strong&gt;&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top"&gt;&lt;p&gt;CBER&lt;/p&gt;&lt;/td&gt;&lt;td valign="top"&gt;&lt;p&gt;June 12, 2012&lt;/p&gt;&lt;/td&gt;&lt;td valign="top"&gt;&lt;p&gt;12 p.m. to 4:30 p.m.&lt;/p&gt;&lt;/td&gt;&lt;td valign="top"&gt;&lt;p&gt;National Institutes of Health, 9000 Wisconsin Avenue, Bethesda, MD&amp;nbsp; 20892; Building 29, Conference Room 121&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;h3&gt;Agenda&lt;/h3&gt;&lt;p&gt;On June 12, 2012 from 12 p.m. to approximately 3:45 p.m., the Committee will meet, by teleconference, in open session, to hear updates on the research programs of the Laboratory of Emerging Pathogens and the Laboratory of Bacterial and Transmissible Spongiform Encephalopathy Agents, Division of Emerging and Transfusion Transmitted Diseases, Office of Blood Research and Review, Center for Biologics Evaluation and Research, FDA. From approximately 3:45 p.m. to 4:30 p.m., the meeting will be closed to permit discussion where disclosure would constitute a clearly unwarranted invasion of personal privacy (5 U.S.C. 552b(c)(6)). The committee will discuss the site visit report of the intramural research programs and make recommendations regarding personnel staffing decisions.&lt;/p&gt;&lt;h3&gt;Meeting Materials&lt;/h3&gt;&lt;p&gt;Materials for this meeting will be available on the &lt;a href="http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/BloodProductsAdvisoryCommittee/ucm298652.htm"&gt;Blood Products Advisory Committee page&lt;/a&gt;.&lt;/p&gt;&lt;h3&gt;Public Participation Information&lt;/h3&gt;&lt;p&gt;Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee.&lt;/p&gt;&lt;ul&gt;&lt;li&gt;Written submissions may be made to the contact person on or before June 1, 2012&lt;/li&gt;&lt;li&gt;Oral presentations from the public will be scheduled between approximately 2:30 p.m. and 3:30 p.m. Those desiring to make formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before May 24, 2012. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by May 25, 2012.&lt;/li&gt;&lt;/ul&gt;&lt;h3&gt;Contact Information&lt;/h3&gt;&lt;ul&gt;&lt;li&gt;LCDR Bryan Emery or Rosanna Harvey&lt;br /&gt;1401 Rockville Pike, HFM-71, Rockville, MD 20852&lt;br /&gt;301-827-0314&lt;br /&gt;FAX: 301-827-0294&lt;br /&gt;e-mail: &lt;a href="mailto:bryan.emery@fda.hhs.gov"&gt;bryan.emery@fda.hhs.gov&lt;/a&gt;; &lt;a href="mailto:rosanna.harvey@fda.hhs.gov"&gt;rosanna.harvey@fda.hhs.gov&lt;/a&gt;&lt;/li&gt;&lt;li&gt;FDA Advisory Committee Information Line&lt;br /&gt;1-800-741-8138 (301-443-0572 in the Washington, DC, area)&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;Please call the Information Line for up-to-date information on this meeting.&lt;/p&gt;&lt;p&gt;FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA's Web site after the meeting.&lt;/p&gt;&lt;p&gt;A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the agency's Web site and call the appropriate advisory committee hot line/phone line to learn about possible modifications before coming to the meeting.&lt;/p&gt;&lt;p&gt;The public is welcome to attend the meeting at the specified location where a speakerphone will be provided. Public participation in the meeting is limited to the use of the spearkerphone in the conference room. Important information about transportation and directions to the NIH campus, parking and security procedures is available on the &lt;a href="http://www.nih.gov/about/visitor/index.htm"&gt;NIH's Visitor Information&lt;/a&gt; page. (FDA has verified the Web site address, but FDA is not responsible for any subsequent changes to the Web site after this document publishes in the Federal Register). Visitors must show two forms of identification, one of which must be a government-issued photo identification such as a Federal employee badge, driver's license, passport, green card, etc. Detailed information about security procedures is located on the &lt;a href="http://www.nih.gov/about/visitorsecurity.htm"&gt;NIH Visitors and Security&lt;/a&gt; page. Due to the limited available parking, visitors are encouraged to use public transportation.&lt;/p&gt;&lt;p&gt;Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets. FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Bryan Emery at least 7 days in advance of the meeting. FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at for procedures on &lt;a href="http://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm"&gt;Public Conduct During FDA Advisory Committee Meetings&lt;/a&gt;.&lt;/p&gt;&lt;p&gt;Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).&lt;/p&gt;</wcm:element>
<wcm:element name="MainList1"></wcm:element>
  <wcm:element name="MainList2"></wcm:element>
  <wcm:element name="MainList3"></wcm:element>
</wcm:root>
